Below 1⃣9⃣3⃣5⃣
Short Gold
Now Cmp: 1⃣9⃣4⃣4⃣
Comex Gold...
Follow Rules If I Have Given Then You Will Be Millionaire
It My Promise
Friday, November 6, 2020
Past Performance Of Given Calls On This Blog Till 6th November 2020
Its My Promise ``NO ONE CAN GIVE BEST THEN ME``.
Profit/Loss Report Of Live Trades Given To You
* MCX Gold +88000/-Rs.
* MCX Zinc +31500/-Rs.
* MCX CrudeOil -68000/-Rs.
* BankNifty +31500/-Rs.
* NaturalGas +26000/-Rs.
* HDFC Call Option -48000/-Rs.
* Nifty -82800/-Rs.
* MCX Zinc +31500/-Rs.
* MCX CrudeOil -68000/-Rs.
* BankNifty +31500/-Rs.
* NaturalGas +26000/-Rs.
* HDFC Call Option -48000/-Rs.
* Nifty -82800/-Rs.
* IGL +73425/-Rs.
* TataGlobal +109200/-Rs.
* Lead +31250/-Rs.
* BharatForg +46800/-Rs.
* YesBank +55440/-Rs.
* TataMotors Ce +75000/-Rs
* Nickel +30000/-Rs
* CrudeOil +32500/-Rs
* Silver +75000/-Rs
* PFC +78120/-Rs
* Zinc +57000/-Rs
* MCX Gold +68000/-Rs
* MCX NaturalGas +44250/-Rs
* Nifty CE Option +71250/-Rs
* Tatamotors +35100/-Rs
* CrudeOil +64000/-Rs
* CrudeOil +47500/-Rs
* MCX Gold +64000/-Rs
* MCX NaturalGas +75000/-Rs
* L&T +86400/-Rs
* MCX Copper +82500/-Rs
* L&TFh +145600/-Rs
* BHEL +76810/-Rs
* NATURALGAS +52500/-Rs
* Nifty CE +38250/-Rs
* Nifty CE +25875/-Rs
* Nifty CE -140250/-Rs.
* MCX CrudeOil +75000/-Rs.
* Nifty Future +106875/-Rs
* MCX CrudeOil +78000/-Rs.
* MCX ZincMini +75000/-Rs.
* NATURALGAS +52500/-Rs
* MCX CrudeOil +52500/-Rs.
* MCX Zinc +100000/-Rs.
* MCX Copper +97500/-Rs
* Reliance +247450/-Rs.
* Nifty Future +54000/-Rs.
* MCX CrudeOil +00000/-Rs.
* Reliance +66370/-Rs.
* MCX Zinc +00000/-Rs.
* MCX NaturalGas -71875/-Rs.
* Titan +126000/-Rs.
* SBIN +69600/-Rs.
* HindUniLvr CE +38700/-Rs.
* LicHsgFin CE -69000/-Rs.
* City Union Bank Cash +73500/-Rs.
Net P/L Report +Rs. 2650840/-
Open Positions:
# MCX CrudeOil November
# MCX Nickel November
# INFY Future November
Join Super Signature #HNITrades For Huge Return, Call
09980555517
Now Book CUB At 164
Given To All Of You As A Free Trial Live Trades On 17th October 2020
City Union Bank Ltd.
3500 Quantity Bought At 143
Now CMP: 164
NOW MY TARGET ACHIEVED..
Book Full Profit
Call Closed
Return: Rs. 73500/-
ROCKED AGAIN AND AGAIN...
Pay Now And Join Super Signature HNI Positional Profit Plan, Call
09980555517
Wednesday, November 4, 2020
SBI Q2 profit surges 52% to Rs 4,574 crore, NII increases to Rs 28,181 crore
State Bank of India (SBI), the largest lender in India, on November 4 registered a significant 51.9 percent year-on-year growth in standalone profit for September quarter, driven by lower provisions and tax cost, and higher net interest income.
Standalone profit increased to Rs 4,574 crore during the quarter, compared to Rs 3,012 crore in the year-ago period, beating analysts' expectations.
Net interest income - the difference between interest earned and interest expended - climbed 14.6 percent year-on-year to Rs 28,181.5 crore in Q2FY21 with credit growth at 6.02 percent YoY and net interest margin at 3.34 percent for the quarter.
The deposits grew by 14.41 percent YoY, with current account deposit
rising by 8.55 percent YoY and saving bank deposits up by 16.28 percent YoY, said the bank.
Numbers were ahead of CNBC-TV18 poll estimates which were pegged at Rs 3,682.3 crore for profit and Rs 27,014 crore for net interest income.
"Bank has delivered a strong performance in Q2FY21 with all round improvement in profitability, capital adequacy and provision coverage ratio, including additional provision over minimum regulatory provisions required," said SBI.
On the asset quality front, the bank said gross non-performing assets as a percentage of gross advances declined 16 bps sequentially to 5.28 percent and net NPA fell 27 bps QoQ to 1.59 percent in the quarter ended September 2020.
Following the Supreme Court order dated September 3, 2020, the bank has not declared any domestic loan account as NPA which was standard as of August 31, 2020.
But the gross NPA and net NPA would have been at 5.88 percent and 2.08 percent respectively for the quarter, if the bank had classified the loan accounts as NPA after August 2020, in accordance with the Income Recognition and Asset Classification (IRAC) norms of the RBI, SBI said.
The fresh slippages dropped to Rs 2,756 crore in September quarter, compared to Rs 3,637 crore reported in June quarter, while gross slippages, too, declined to Rs 3,085 crore in September quarter, against Rs 3,910 crore registered in previous quarter.
Provisions and contingencies for the quarter at Rs 10,118 crore declined 23 percent compared to year-ago period and the sequential fall was 19.1 percent in Q2FY21.
Provision coverage ratio improved further to 88.19 percent as of September 2020, from 86.3 percent in June quarter. "The provision coverage ratio would be 85.25 percent, if the bank had followed the IRAC norms," SBI said in its BSE filing.
State Bank of India has made additional provisions of Rs 239 crore on COVID related accounts in Q2, taking the total COVID related provision at Rs 3,247 crore.
The pre-provision operating profit in Q2 increased 11.9 percent to Rs 16,459.76 crore compared to previous year. The pre-provision operating profit in Q2FY20 was boosted by the stake sale in SBI Life Insurance Company.
Non-interest income fell 0.1 percent year-on-year to Rs 8,527.69 crore during the quarter, while tax expenses reduced 13.7 percent YoY to Rs 1,767.3 crore in the quarter ended September 2020.
Earlier this month, the government appointed Dinesh Kumar Khara (currently Managing Director) as the Chairman of State Bank of India for a period of three years.
The worries over NPA, delay in stressed accounts resolution and loan growth slowdown continued to weigh on the banking sector, especially PSU banks.
As a result, the stock price has not seen any major movement in the current financial year, so far, as it was around Rs 200-levels now against the closing of Rs 196.85 on March 31 this year, while it gained just 4 percent during the September quarter.
The stock price corrected 1.25 percent to Rs 202.20 on the BSE at 14:03 hours IST.
GAIL Future November Buy At 84.30
GAIL Future November
Buy 2 Lots At 84.30
Now LTP: 84.30
HOLD FOR TARGET 105
Lot Size: 6100
Total Quantity: 12200
Pay Now & Join Super Signature HNI Positional Profit Plan, Call
09980555517
Ask Bank Details For Subscriptions On Whats App Only
09900017008
Tuesday, November 3, 2020
Yes Bank in talks with ARCs to sell NPAs worth over Rs 32,000 crore: Report
Troubled private sector lender Yes Bank is in discussions with several asset reconstruction companies (ARCs) to sell off bad loans worth Rs 32,344 crore. It has appointed EY as an advisor for the bids, Business Standard reported.
Yes Bank has already made provisions for 76 percent of its gross non-performing assets (NPAs) worth Rs 24,476 crore and is looking at the sale to “regain its place” in India’s banking sector, the report noted.
Yes Bank and EY did not respond to queries, as per the report.
The move comes after the private lender sold bonds held in Dewan Housing Finance (DHFL) in the secondary market to raise Rs 500 crore and reduce exposure to the troubled non-banking financial company (NBFC). It is also looking to sell its mutual funds by 2020-end to raise more capital.
Besides this, the bank is also in talks with strategic investors to set up its own ARC to house NPAs, the report added.
The “clean-up process” has been on since the Reserve Bank of India (RBI) superseded the entire board of Yes Bank in March. Since then, the lender was brought under new management and successfully raised Rs 15,000 crore through IPO route and over Rs 5,500 crore through long-term refinancing borrowing.
Sun Pharma Q2 earnings beat the Street as profit surges 70% to Rs 1,813 crore
Drug major Sun Pharmaceutical Industries on November 3 reported a massive 70.4 percent year-on-year growth in consolidated profit driven by operating performance and tax credit, though forex loss limited growth.
Consolidated profit increased to Rs 1,813 crore in quarter ended September 2020, compared to Rs 1,064 crore in same period last year.
Sun Pharma in its BSE filing said tax gain (exceptional) for the quarter ended September 2020 was on account of creation of deferred tax asset amounting to Rs 288.28 crore arising out of subsequent measurement attributable to restructuring of an acquired entity.
The company had a forex loss of Rs 116.4 crore during the quarter, against forex gain of Rs 8.5 crore in Q2FY20, it added.
Consolidated revenue from operations grew by 5.3 percent year-on-year to Rs 8,553 crore in September quarter.
At the operating level, its earnings before interest, tax, depreciation and amortisation (EBITDA) in Q2 surged 22.5 percent to Rs 2,193.3 crore and margin expanded 360 bps to 25.6 percent compared to corresponding quarter of previous financial year.
Numbers were ahead of analysts' expectations for the quarter. Profit was estimated at Rs 1,124 crore on revenue of Rs 8,189 crore and EBITDA was expected at RS 1,830 crore with margin at 22.3 percent, as per the avearge of estimates of analysts polled by CNBC-TV18.
Sun Pharma said its debt equity ratio (long-term borrowings + short-term borrowings + current maturities of long-term borrowings) / (Total equity) was reduced to 0.13 percent as of September 2020, compared to 0.18 percent at the end of March 2020, while net worth droped to Rs 44,699.84 crore at the end of September, from Rs 44,891.90 crore in March this year.
The stock was trading at Rs Rs 482.10, up 2.75 percent on the BSE at 15:07 hours IST.
Subscribe to:
Posts (Atom)